| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Polly A. Murphy is Director at AVIR and has filed Form 4s across 2 companies. Polly A. Murphy's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $963K at current prices.
The biggest single holding is AVIR (~$508K) as Director. Net of sales, the AVIR filings show accumulation of 18,100 shares.
Polly A. Murphy has 18 Form 4 filings on record from November 2020 to June 2026, across 2 companies: Director at Atea Pharmaceuticals (AVIR), 2020–2026; Director at Celcuity (CELC), 2022–2026.
The 31 reported transactions were 15 option or other derivative awards, 8 gifts, 3 option exercises and 3 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $177K and no sales.
The largest open-market purchase was 12,000 shares of AVIR at an average $8.57 on December 20, 2021, about $103K. Twelve months later AVIR was down 47%.